{"id":"methylprednisolone-drug","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia and mood disturbances"},{"rate":null,"effect":"Increased infection risk"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Cushingoid features (with chronic use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylprednisolone acts as a corticosteroid that penetrates cells and binds to cytoplasmic glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This results in decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and proliferation. It is commonly used for its potent anti-inflammatory and immunosuppressive effects across multiple therapeutic areas.","oneSentence":"Methylprednisolone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:53.772Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, vasculitis)"},{"name":"Acute exacerbations of multiple sclerosis"},{"name":"Cerebral edema"},{"name":"Allergic reactions and asthma exacerbations"},{"name":"Hematologic malignancies (as adjunctive therapy)"},{"name":"Organ transplant rejection prophylaxis"}]},"trialDetails":[{"nctId":"NCT03856229","phase":"NA","title":"Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS","status":"ENROLLING_BY_INVITATION","sponsor":"Centro de Investigación en. Enfermedades Infecciosas, Mexico","startDate":"2019-03-04","conditions":"Pneumocystis, HIV/AIDS, Steroid","enrollment":196},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT06925737","phase":"PHASE3","title":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":1440},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT07496060","phase":"PHASE4","title":"Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2025-08-10","conditions":"Anterior Chamber Granulomatous Uveitis","enrollment":66},{"nctId":"NCT05462730","phase":"PHASE2","title":"Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"Thomas Engstrom","startDate":"2022-11-14","conditions":"ST Elevation Myocardial Infarction, Inflammatory Response, Myocardial Reperfusion Injury","enrollment":530},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":"Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma","enrollment":600},{"nctId":"NCT07497737","phase":"PHASE4","title":"OMT for Adhesive Capsulitis","status":"NOT_YET_RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2026-04-01","conditions":"Adhesive Capsulitis of the Shoulder, Frozen Shoulder","enrollment":300},{"nctId":"NCT07489521","phase":"PHASE4","title":"Arthrosemid vs. Steroid for the Management Knee Osteoarthritis","status":"RECRUITING","sponsor":"Cappagh National Orthopaedic Hospital","startDate":"2026-03","conditions":"Osteo Arthritis Knee, Osteoarthritis, Intraarticular Injection","enrollment":200},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT07498842","phase":"NA","title":"Corticosteroid Tapering in Sarcoidosis","status":"RECRUITING","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","startDate":"2026-03-19","conditions":"Sarcoidosis","enrollment":100},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT07412470","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-03-13","conditions":"Kidney Transplant Rejection","enrollment":526},{"nctId":"NCT05139316","phase":"PHASE3","title":"A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2021-11-08","conditions":"Glycogen Storage Disease Type IA","enrollment":49},{"nctId":"NCT06365853","phase":"PHASE2","title":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-29","conditions":"Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive","enrollment":100},{"nctId":"NCT07270549","phase":"PHASE1, PHASE2","title":"Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome","status":"RECRUITING","sponsor":"CTNNB1 Foundation","startDate":"2025-11-01","conditions":"CTNNB1 Neurodevelopmental Syndrome","enrollment":12},{"nctId":"NCT06421935","phase":"PHASE1","title":"M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-08-07","conditions":"Advanced Solid Tumor","enrollment":141},{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT05123040","phase":"PHASE1, PHASE2","title":"Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-06-05","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT06235567","phase":"PHASE1, PHASE2","title":"Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking","status":"ENROLLING_BY_INVITATION","sponsor":"Maanasa Indaram, MD","startDate":"2025-04-11","conditions":"Keratoconus","enrollment":20},{"nctId":"NCT06936566","phase":"PHASE2","title":"MAGIC Ruxolitinib for aGVHD","status":"RECRUITING","sponsor":"John Levine","startDate":"2025-05-14","conditions":"Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects","enrollment":98},{"nctId":"NCT07255248","phase":"PHASE4","title":"Hoffa's Fat Pad Impingement (HFPI)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-03-01","conditions":"Hoffa's Fat Pad Impingement","enrollment":62},{"nctId":"NCT06388564","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2024-10-11","conditions":"Chronic Graft-versus-host-disease","enrollment":120},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT05489211","phase":"PHASE2","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-06","conditions":"Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":454},{"nctId":"NCT06892197","phase":"PHASE4","title":"Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)","status":"RECRUITING","sponsor":"Copenhagen Respiratory Research","startDate":"2026-03-10","conditions":"Community Acquired Pneumonia (CAP)","enrollment":1600},{"nctId":"NCT06892210","phase":"PHASE4","title":"Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)","status":"RECRUITING","sponsor":"Copenhagen Respiratory Research","startDate":"2026-03-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":2000},{"nctId":"NCT07478003","phase":"PHASE3","title":"Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial","status":"NOT_YET_RECRUITING","sponsor":"Thomas Engstrom","startDate":"2026-04-01","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":5204},{"nctId":"NCT07287397","phase":"PHASE1, PHASE2","title":"Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS","status":"RECRUITING","sponsor":"Vector Y Therapeutics","startDate":"2025-12-19","conditions":"Amyotrophic Lateral Sclerosis","enrollment":12},{"nctId":"NCT01679119","phase":"PHASE2","title":"Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-10","conditions":"Diffuse Large B Cell Lymphoma","enrollment":129},{"nctId":"NCT05435781","phase":"PHASE4","title":"Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency","status":"RECRUITING","sponsor":"Marianne Christina Klose","startDate":"2022-06-07","conditions":"Adrenal Insufficiency, Polymyalgia Rheumatica, Giant Cell Arteritis","enrollment":250},{"nctId":"NCT07472309","phase":"","title":"Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-06-06","conditions":"Ulcerative Colitis (UC), Acute Severe Ulcerative Colitis, Upadacitinib","enrollment":81},{"nctId":"NCT06585774","phase":"PHASE3","title":"A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-01-21","conditions":"Chronic Graft-versus-host-disease","enrollment":240},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT04300556","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","status":"RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-08-06","conditions":"Solid Tumor","enrollment":182},{"nctId":"NCT07052929","phase":"PHASE1, PHASE2","title":"Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators","status":"RECRUITING","sponsor":"Astellas Gene Therapies","startDate":"2025-12-15","conditions":"X-Linked Myotubular Myopathy","enrollment":9},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT04127578","phase":"PHASE1, PHASE2","title":"Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prevail Therapeutics","startDate":"2020-01-03","conditions":"Parkinson Disease","enrollment":32},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT03661645","phase":"PHASE4","title":"Post-operative Methylprednisolone Taper Course for Orthopedic Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Emory University","startDate":"2018-09-07","conditions":"Orthopedic Surgeries","enrollment":500},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT05944861","phase":"NA","title":"Combination of Fluoroscopy and Ultrasonography Guidance in Sacroiliac Joint Injections. A Randomised Controlled Trial","status":"COMPLETED","sponsor":"Gaziler Physical Medicine and Rehabilitation Education and Research Hospital","startDate":"2023-02-15","conditions":"Sacroiliac Joint Somatic Dysfunction, Sacroiliac Joint Pain","enrollment":38},{"nctId":"NCT05171816","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":110},{"nctId":"NCT07100990","phase":"PHASE3","title":"Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-07-11","conditions":"Optic Neuritis, Myelitis, Myelitis, Transverse","enrollment":382},{"nctId":"NCT07461961","phase":"PHASE2","title":"CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-07-01","conditions":"Cardiogenic Shock, Heart Failure, Inflammation","enrollment":30},{"nctId":"NCT04862221","phase":"PHASE2","title":"TReatment for ImmUne Mediated PathopHysiology","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2022-02-09","conditions":"Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy","enrollment":163},{"nctId":"NCT05807048","phase":"PHASE2","title":"Daratumumab in STK11 Mutated NSCLC","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-06-01","conditions":"Non-small Cell Lung Cancer With STK11/LKB1 Mutation","enrollment":8},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT06952803","phase":"PHASE3","title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-06","conditions":"Prostate Cancer","enrollment":700},{"nctId":"NCT06780202","phase":"PHASE2","title":"Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-27","conditions":"Foot Injuries and Disorders, Ankle Injuries and Disorders, Achilles Tendon Injury","enrollment":180},{"nctId":"NCT07454772","phase":"PHASE1, PHASE2","title":"Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis","status":"NOT_YET_RECRUITING","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2026-03-15","conditions":"Granulomatous Mastitis","enrollment":72},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT07455396","phase":"PHASE2","title":"Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins All Children's Hospital","startDate":"2026-05-15","conditions":"Asthma (Diagnosis)","enrollment":159},{"nctId":"NCT05734625","phase":"PHASE2","title":"Efficacy of Nerve Blocks for Episodic Migraine","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-07-10","conditions":"Episodic Migraine","enrollment":60},{"nctId":"NCT04206553","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-10-28","conditions":"Bullous Pemphigoid","enrollment":106},{"nctId":"NCT07245732","phase":"PHASE4","title":"Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-04","conditions":"Rheumatoid Arthritis (RA)","enrollment":220},{"nctId":"NCT02464696","phase":"NA","title":"Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-10-06","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":256},{"nctId":"NCT05800366","phase":"PHASE2","title":"A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-04-06","conditions":"Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":41},{"nctId":"NCT06624670","phase":"PHASE3","title":"A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-02-04","conditions":"Pyoderma Gangrenosum","enrollment":90},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT07197749","phase":"EARLY_PHASE1","title":"Vitamin C With Steroids for Gastrointestinal GVHD","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-06","conditions":"Graft-versus-host-disease (GVHD), Gastrointestinal","enrollment":35},{"nctId":"NCT05789589","phase":"PHASE1, PHASE2","title":"Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2023-11-17","conditions":"Cancer, Metastasis, Metastatic Cancer","enrollment":46},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT07221838","phase":"PHASE4","title":"A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab","status":"NOT_YET_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2026-02-27","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":75},{"nctId":"NCT07005154","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-06-19","conditions":"Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer","enrollment":218},{"nctId":"NCT04597125","phase":"PHASE4","title":"RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2020-11-09","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":654},{"nctId":"NCT05674994","phase":"PHASE3","title":"Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2023-10-26","conditions":"Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":110},{"nctId":"NCT04977427","phase":"PHASE4","title":"Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2021-08-31","conditions":"Cataract Diabetic, Macula Edema","enrollment":""},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT07087314","phase":"PHASE2","title":"A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence","status":"RECRUITING","sponsor":"Mao Jianhua","startDate":"2025-08-25","conditions":"Nephrotic Syndrome in Children","enrollment":30},{"nctId":"NCT04438382","phase":"PHASE2","title":"Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-01-07","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis","enrollment":1},{"nctId":"NCT03725202","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-01-24","conditions":"Giant Cell Arteritis (GCA)","enrollment":429},{"nctId":"NCT07291089","phase":"PHASE4","title":"Iris Vascular Area Density-Based Preoperative Pain-Risk Screening and Intervention in Second-Eye Cataract Surgery","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-02-23","conditions":"Age Related Cataract, Pain Management During Cataract Surgery","enrollment":126},{"nctId":"NCT03286556","phase":"PHASE2","title":"Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-09-04","conditions":"Idiopathic Pulmonary Fibrosis, Acute Fatal Form","enrollment":82},{"nctId":"NCT06356571","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-17","conditions":"Plasma Cell Myeloma Refractory","enrollment":64},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT03755804","phase":"PHASE2","title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-12-12","conditions":"Hodgkin Lymphoma","enrollment":232},{"nctId":"NCT04876651","phase":"PHASE3","title":"The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only","status":"TERMINATED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","startDate":"2023-08-29","conditions":"Metastatic Prostate Cancer","enrollment":16},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT05626478","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2023-06-01","conditions":"Corneal Edema, Corneal Defect, Anterior Chamber Inflammation","enrollment":50},{"nctId":"NCT07199192","phase":"PHASE4","title":"Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-03-01","conditions":"Hypoxemia, Severe Acute Respiratory Syndrome","enrollment":3000},{"nctId":"NCT07268248","phase":"NA","title":"1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study","status":"NOT_YET_RECRUITING","sponsor":"Paul Peng, MD PhD MSCR","startDate":"2026-06","conditions":"Allergic Reaction to Contrast Media, Hypersensitivity Reaction, Computed Tomography","enrollment":540},{"nctId":"NCT03407144","phase":"PHASE2","title":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-09","conditions":"Hodgkin Lymphoma","enrollment":340},{"nctId":"NCT07420296","phase":"PHASE4","title":"Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-01-01","conditions":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":198},{"nctId":"NCT07393503","phase":"PHASE4","title":"Musculoskeletal Outcomes Using Tylenol/Ibuprofen vs. Oral Steroids in New Injuries","status":"ENROLLING_BY_INVITATION","sponsor":"State University of New York at Buffalo","startDate":"2025-09-17","conditions":"Musculoskeletal Pain","enrollment":60},{"nctId":"NCT04161898","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-02-04","conditions":"Takayasu Arteritis (TAK)","enrollment":56},{"nctId":"NCT04980222","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-22","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT05345171","phase":"PHASE3","title":"Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2022-10-18","conditions":"OTC Deficiency","enrollment":32},{"nctId":"NCT07411950","phase":"NA","title":"EuroPainClinicsStudy IX ( EPCS IX )","status":"COMPLETED","sponsor":"EPC Education s.r.o.","startDate":"2021-01-01","conditions":"Failed Back Surgery Syndrome, Lumbar Radiculopathy, Chronic Low Back Pain","enrollment":141},{"nctId":"NCT04544436","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-26","conditions":"Multiple Sclerosis","enrollment":864},{"nctId":"NCT07217405","phase":"PHASE4","title":"Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-12-19","conditions":"Osteoarthritis Hand, Osteoarthritis Wrist","enrollment":165},{"nctId":"NCT00400946","phase":"PHASE3","title":"05-001: Treatment of Acute Lymphoblastic Leukemia in Children","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-04","conditions":"Drug/Agent Toxicity by Tissue/Organ, Leukemia","enrollment":800},{"nctId":"NCT07406932","phase":"NA","title":"A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2026-02-01","conditions":"Antisynthetase Syndrome, Interstitial Lung Disease (ILD)","enrollment":80},{"nctId":"NCT07258524","phase":"","title":"PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2026-01-28","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":120},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT03384277","phase":"PHASE4","title":"Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2017-12-29","conditions":"Acquired Hemophilia A","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2835,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Methylprednisolone (drug)","genericName":"Methylprednisolone (drug)","companyName":"University Hospital, Bordeaux","companyId":"university-hospital-bordeaux","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylprednisolone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, vasculitis), Allergic reactions and angioedema, Asthma and chronic obstructive pulmonary disease exacerbations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}